Gene-focused biotechnology player Wuhan Binhui Biotech on Wednesday announced the completion of a 600 million yuan ($93 million) Series C round funding jointly led by healthcare-focussed Share Capital, Temasek’s Vertex Ventures China, Qianhai FOF, and CICC Capital’s sub-fund.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
